Free tool
Stocks near their 52-week high
We cover 60 companies trading within 5% of their own 52-week high. The median market value in the group is $38.19B. Across the group, the median move over the past trading day is −0.05%. 100% of the 60 with a 200-day average trade above it. Price change over the past year runs from +20.9% to +130.2% across the middle 80 percent of the group, with a median of +44.3%.
Other lists in this group
Table
60 of 3,992 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | $658.24B | Mega cap | +55.40% |
| JNJB34.SA | Johnson & Johnson | $658.09B | Mega cap | +47.82% |
| ABBV | AbbVie Inc. | $469.68B | Mega cap | +29.36% |
| ABBV34.SA | AbbVie Inc. | $467.00B | Mega cap | +21.88% |
| MRCK34.SA | Merck & Co., Inc. | $388.60B | Mega cap | +81.07% |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% |
| AMGN34.SA | Amgen Inc. | $239.09B | Mega cap | +47.79% |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% |
| PFIZ34.SA | Pfizer Inc. | $161.53B | Large cap | +11.58% |
| PFE | Pfizer Inc. | $161.30B | Large cap | +18.72% |
| BMYB34.SA | Bristol-Myers Squibb Company | $138.65B | Large cap | +40.74% |
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% |
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| REGN34.SA | Regeneron Pharmaceuticals, Inc. | $85.16B | Large cap | +33.80% |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.89B | Large cap | +39.36% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| A1RG34.SA | argenx SE | $63.16B | Large cap | +36.97% |
| TAK | Takeda Pharmaceutical Company Limited | $58.60B | Large cap | +22.68% |
| TAKP34.SA | Takeda Pharmaceutical Company Limited | $57.22B | Large cap | +18.03% |
| C1AH34.SA | Cardinal Health, Inc. | $55.77B | Large cap | +52.41% |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| T1EV34.SA | Teva Pharmaceutical Industries Limited | $44.24B | Large cap | +94.70% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.19B | Large cap | +110.08% |
| A | Agilent Technologies, Inc. | $43.80B | Large cap | +31.46% |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| WAT | Waters Corporation | $40.67B | Large cap | +40.57% |
| RPRX | Royalty Pharma plc | $35.71B | Large cap | +74.00% |
| I1LM34.SA | Illumina, Inc. | $34.10B | Large cap | +113.13% |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% |
| D1EX34.SA | DexCom, Inc. | $33.75B | Large cap | +9.64% |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +16.47% |
| BIIB | Biogen Inc. | $32.66B | Large cap | +62.12% |
| C1NC34.SA | Centene Corporation | $32.65B | Large cap | +116.61% |
| BIIB34.SA | Biogen Inc. | $32.56B | Large cap | +47.86% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| I1NC34.SA | Incyte Corporation | $25.83B | Large cap | +41.91% |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +50.70% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| SOLV | Solventum Corporation | $15.58B | Large cap | +25.57% |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +42.93% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +4.97% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% |
| T1CH34.SA | Bio-Techne Corporation | $11.51B | Large cap | +23.42% |
| TECH | Bio-Techne Corporation | $11.35B | Large cap | +29.33% |
| PRAX | Praxis Precision Medicines, Inc. | $10.54B | Large cap | +704.28% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% |
| HSIC | Henry Schein, Inc. | $10.30B | Large cap | +31.02% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.